A5024390084- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Inflammatory Bowel Disease
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
- Microscopic Colitis
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Esophageal Cancer Research and Treatment
- Hepatitis C virus research
- Economic and Financial Impacts of Cancer
- Cancer-related Molecular Pathways
- Immunotherapy and Immune Responses
Antwerp University Hospital
2016-2025
University of Antwerp
2016-2025
MSD (Netherlands)
2025
Sciensano (Belgium)
2024
Université Libre de Bruxelles
2009-2024
Ghent University Hospital
2005-2023
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2007-2023
Ontario Brain Institute
2023
European Organisation for Research and Treatment of Cancer
2010-2022
Integrated Oncology (United States)
2022
Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations KRAS, small G-protein downstream EGFR, correlate poor response to anti-EGFR antibodies mCRC, their role as selection marker not been established randomized trials.
Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR). We compared activity of panitumumab plus best supportive care (BSC) to that BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy.We randomly assigned 463 1% or more EGFR tumor cell membrane staining, measurable disease, and radiologic documentation disease progression during within 6 months most recent chemotherapy mg/kg every 2...
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent combines trifluridine and tipiracil hydrochloride, was effective the treatment of refractory colorectal cancer. We a phase 3 trial to further assess efficacy safety TAS-102 global population such patients.In this double-blind study, we randomly assigned 800 patients, 2:1 ratio, receive or placebo. The primary end point overall survival.The median survival improved from 5.3 months with placebo 7.1 hazard...
Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, irinotecan (FOLFIRI) compared with FOLFIRI alone after failure initial treatment for mCRC by tumor KRAS status. Patients Methods mCRC, one prior chemotherapy regimen Eastern Cooperative...
PURPOSE: A prospective study of preoperative tumor-node-metastasis staging patients with esophageal cancer (EC) was designed to compare the accuracy 18-F-fluoro-deoxy-d-glucose (FDG) positron emission tomography (PET) conventional noninvasive modalities. PATIENTS AND METHODS: Seventy-four carcinomas esophagus (n = 43) or gastroesophageal junction 31) were studied. All underwent attenuation-corrected FDG-PET imaging, a spiral computed (CT) scan, and an endoscopic ultrasound (EUS). RESULTS:...
Liver dissemination is a major cause of mortality among patients with advanced colorectal cancer. Hepatic intra-arterial injection the beta-emitting isotope yttrium-90 ((90)Y) bound to resin microspheres (radioembolization) delivers therapeutic radiation doses liver metastases minimal damage adjacent tissues.We conducted prospective, multicenter, randomized phase III trial in unresectable, chemotherapy-refractory liver-limited metastatic CRC (mCRC) comparing arm A (fluorouracil [FU]...
To study the power of epidermal growth factor receptor (EGFR) epiregulin (EREG) and amphiregulin (AREG) ligands' expression in primary tumors to predict outcome patients with chemorefractory metastatic colorectal cancer (cmCRC) treated combination cetuximab irinotecan.Gene measurements KRAS mutation analysis were performed on archival formalin-fixed paraffin-embedded 220 cmCRC patients. Response was measured using RECIST (Response Evaluation Criteria Solid Tumors) criteria. The relation...
Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit patients with liver metastases liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy SIRT using yttrium-90 resin microspheres metastases. were designed combined analysis overall survival.
SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres standard fluorouracil, leucovorin, oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer.Chemotherapy-naïve liver metastases plus or minus limited extrahepatic were randomly assigned receive either modified FOLFOX (mFOLFOX6; control) mFOLFOX6 SIRT bevacizumab. The...
The role of adjuvant chemoradiotherapy (CRT) in resectable pancreatic cancer is still debated. This randomized phase II intergroup study explores the feasibility and tolerability a gemcitabine-based CRT regimen after R0 resection head cancer.Within 8 weeks surgery, patients were randomly assigned to receive either four cycles gemcitabine (control arm) or for two followed by weekly with concurrent radiation (50.4 Gy; arm). primary objective was exclude < 60% treatment completion > 40% rate...
Background Cell viability and motility comprise ubiquitous mechanisms involved in a variety of (patho)biological processes including cancer. We report technical comparative analysis the novel impedance-based xCELLigence Real-Time Analysis detection platform, with conventional label-based endpoint methods, hereby indicating performance characteristics correlating dynamic observations cell proliferation, cytotoxicity, migration invasion on cancer cells highly standardized experimental...
To investigate whether EGF receptor (EGFR) pathway mutations predicted response to monotherapy with panitumumab, an anti-EGFR monoclonal antibody, in a randomized phase III study of metastatic colorectal cancer.Using massively parallel multigene sequencing, we analyzed 320 samples for 9 genes, sequence data from 288 (90%) samples.Mutation rates were: KRAS (45%), NRAS (5%), BRAF (7%), PIK3CA (9%), PTEN (6%), TP53 (60%), EGFR (1%), AKT1 (<1%), and CTNNB1 (2%). In the open-label extension, 22...
Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has demonstrated significant improvements in progression-free survival (PFS) patients with wild-type KRAS metastatic colorectal cancer (mCRC) studies 20050203 (first line), 20050181 (second and 20020408 (monotherapy). Mutations codons 12 13 are recognized biomarkers that predict lack of response to anti-EGFR therapies. This retrospective analysis three randomized phase III assessed...